TROP-2-Directed ADC Could Be New Standard for Some NSCLCs.

In newly diagnosed PD-L1–negative advanced nonsquamous NSCLC without targetable alterations, sacituzumab tirumotecan plus pembrolizumab achieved median PFS of 15 months versus 5.7 months with chemotherapy plus pembrolizumab.

• Why it matters: A major need remains for more effective first-line options in this biomarker-defined subgroup, where outcomes with standard chemotherapy plus PD-1 blockade are limited.
• What they did: In the phase III Opti-TROP-Lung06 trial, investigators compared sacituzumab tirumotecan combined with pembrolizumab against standard chemotherapy combined with pembrolizumab, measuring median progression-free survival.
• The result: The 15-month median PFS with the TROP-2–directed ADC regimen indicates improved disease control in this specific patient population and supports further consideration of this approach.

AI summary of the abstract · may contain errors · not medical advice · read the paper.